Risk of secondary progressive multiple sclerosis: A longitudinal study

A Fambiatos; V Jokubaitis; D Horakova; E Kubala Havrdova; M Trojano; A Prat; M Girard; P Duquette; A Lugaresi; G Izquierdo; F Grand’Maison; P Grammond; P Sola; D Ferraro; R Alroughani; M Terzi; R Hupperts; C Boz; J Lechner-Scott; E Pucci; R Bergamaschi; V Van Pesch; S Ozakbas; F Granella; R Turkoglu; G Iuliano; D Spitaleri; P McCombe; C Solaro; M Slee; R Ampapa; A Soysal; T Petersen; JL Sanchez-Menoyo; F Verheul; J Prevost; Y Sidhom; B Van Wijmeersch; S Vucic; E Cristiano; ML Saladino; N Deri; M Barnett; J Olascoaga; F Moore; O Skibina; O Gray; Y Fragoso; B Yamout; C Shaw; B Singhal; N Shuey; S Hodgkinson; A Altintas; T Al-Harbi; T Csepany; B Taylor; J Hughes; JK Jun; A van der Walt; T Spelman; H Butzkueven; T Kalincik

Journal article

Risk of secondary progressive multiple sclerosis: A longitudinal study

A Fambiatos, V Jokubaitis, D Horakova, E Kubala Havrdova, M Trojano, A Prat, M Girard, P Duquette, A Lugaresi, G Izquierdo, F Grand’Maison, P Grammond, P Sola, D Ferraro, R Alroughani, M Terzi, R Hupperts, C Boz, J Lechner-Scott, E Pucci Show all

Multiple Sclerosis Journal | Published : 2020

DOI: 10.1177/1352458519868990

Abstract

Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis. Methods: Patients with adult-onset relapsing–remitting multiple sclerosis and at least four recorded disability scores were selected from MSBase, a global observational cohort. The risk of conversion to objectively defined secondary progressive multiple sclerosis was evaluated at multiple time points per patient using multivariable marginal Cox regression models. Sensitivity..

View full abstract

University of Melbourne Researchers

Neil Shuey Author

Timothy Spelman Author

Tomas Kalincik Author

Related Projects (3)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by National Health and Medical Research Council of Australia (project grants 1083539 and 1129189 and fellowship 1140766). The MSBase Foundation is a not-for-profit organisation that receives support from Merck, Biogen, Roche, Novartis, Bayer Schering, Sanofi Genzyme and Teva. The study was conducted separately and apart from the guidance of the sponsors.